Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608023 · ClinicalTrials.gov registry record · Phase 3
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
A Phase 3 study, sponsored by Theratechnologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 263
- Enrollment target
NCT00608023: Completed Phase 3 study, sponsored by Theratechnologies.
NCT00608023 is a Phase 3 study that has completed, run by Theratechnologies. The registered enrollment target is 263 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608023, a Phase 3 study, has completed, sponsored by Theratechnologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 263 participants
- Enrollment target
Study Summary
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
Primary Outcome
Blood glucose was determined after an overnight fast. Changes in blood glucose between baseline and Week 52 are reported.
Interventions
- DRUG Tesamorelin
- DRUG Placebo for Tesamorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
What the finished NCT00608023 record still lists
NCT00608023 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Tesamorelin is the first listed.
NCT00608023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00608023 about?
NCT00608023 is a clinical study titled "TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy". Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
What is the current status of trial NCT00608023?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 263 participants. The study started on 2007-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00608023?
The interventions under investigation include: Tesamorelin (DRUG), Placebo for Tesamorelin (DRUG).
Who is sponsoring clinical trial NCT00608023?
This trial is sponsored by Theratechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00608023's enrollment target sits among peer trials
263 1228th of 2000 higher than 773 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia